CellCentric Overview
- Year Founded
-
2003
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$219M
- Investors
-
23
CellCentric General Information
Description
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. The company's novel small-molecule inhibitors inhibit the common bromodomain of twin proteins down-regulate the androgen receptor and also deplete the adaptive AR splice variant forms, thereby enabling clients to treat specific cancers and notably relapsed refractory multiple myeloma.
Contact Information
Website
www.cellcentric.comCorporate Office
- Chesterford Research Park
- Cambridge CB10 1XL
- England, United Kingdom
Corporate Office
- Chesterford Research Park
- Cambridge CB10 1XL
- England, United Kingdom
CellCentric Timeline
CellCentric Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 21. Later Stage VC (Series D) | 06-May-2026 | $219M | Completed | Clinical Trials - Phase 1 | ||
| 20. Later Stage VC (Series C) | 22-Apr-2025 | Completed | Clinical Trials - Phase 1 | |||
| 19. Later Stage VC (Series B) | 09-Jul-2024 | Completed | Clinical Trials - Phase 1 | |||
| 18. Later Stage VC (Series A) | 30-Jun-2023 | Completed | Clinical Trials - Phase 1 | |||
| 17. Later Stage VC | 22-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 16. Accelerator/Incubator | 01-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 15. Later Stage VC | 15-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 14. Later Stage VC | 19-Jun-2017 | Completed | Clinical Trials - Phase 1 | |||
| 13. Grant | 08-Nov-2016 | $31.1M | Completed | Clinical Trials - Phase 1 | ||
| 12. Later Stage VC | 28-Jul-2016 | $5.27M | $31.1M | Completed | Clinical Trials - Phase 1 |
CellCentric Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Preferred | ||||||||
| C Preferred | ||||||||
| B-1 Preferred | ||||||||
| B-2 Preferred | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 6,153,846 | $0.001350 | $0.88 | $0.88 | 1x | $0.88 | 4.62% | |
| A Ordinary | 1,482,749 | $0.001350 | $9.13 | $9.13 | 1x | $9.13 | 1.11% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
CellCentric Comparisons
Industry
Financing
Details
CellCentric Competitors (47)
One of CellCentric’s 47 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
CellCentric Patents
CellCentric Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026171694-A1 | Combination therapy for cancer | Pending | 11-Feb-2025 | ||
| GB-201806320-D0 | Process | Inactive | 18-Apr-2018 | ||
| AU-2019256788-A1 | Process for preparing modulators of p300 and/or cbp | Active | 18-Apr-2018 | ||
| AU-2019256788-B2 | Process for preparing modulators of p300 and/or cbp | Active | 18-Apr-2018 | ||
| CA-3096441-A1 | Process for preparing modulators of p300 and/or cbp | Pending | 18-Apr-2018 | C07D413/14 |
CellCentric Signals
CellCentric Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| American Cancer Society | Corporation | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority | ||
| Sofinnova Partners | Venture Capital | Minority | ||
| Venrock | Venture Capital | Minority |
CellCentric FAQs
-
When was CellCentric founded?
CellCentric was founded in 2003.
-
Where is CellCentric headquartered?
CellCentric is headquartered in Cambridge, United Kingdom.
-
What is the size of CellCentric?
CellCentric has 29 total employees.
-
What industry is CellCentric in?
CellCentric’s primary industry is Drug Discovery.
-
Is CellCentric a private or public company?
CellCentric is a Private company.
-
What is the current valuation of CellCentric?
The current valuation of CellCentric is .
-
What is CellCentric’s current revenue?
The current revenue for CellCentric is .
-
How much funding has CellCentric raised over time?
CellCentric has raised $505M.
-
Who are CellCentric’s investors?
American Cancer Society, Fidelity Management & Research Company, HBM Healthcare Investments, Sofinnova Partners, and Venrock are 5 of 23 investors who have invested in CellCentric.
-
Who are CellCentric’s competitors?
Kite Pharma, MaveriX Oncology, Adimab, Carisma Therapeutics, and Adaptimmune Therapeutics are some of the 47 competitors of CellCentric.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process